MediWound (NASDAQ:MDWD) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of MediWound (NASDAQ:MDWD) in a report published on Friday, Benzinga reports. HC Wainwright currently has a $28.00 target price on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. Maxim Group increased their price objective on MediWound from $25.00 to $30.00 and gave the stock a buy rating in a research note on Tuesday, July 16th. StockNews.com raised shares of MediWound to a sell rating in a research report on Monday, August 5th.

MediWound Price Performance

Shares of MDWD opened at $16.81 on Friday. MediWound has a one year low of $7.45 and a one year high of $24.00. The company has a 50-day moving average of $17.60 and a two-hundred day moving average of $17.25. The stock has a market cap of $156.06 million, a price-to-earnings ratio of -12.18 and a beta of 0.83.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.26). MediWound had a negative return on equity of 52.49% and a negative net margin of 99.17%. The firm had revenue of $5.06 million during the quarter, compared to analyst estimates of $5.07 million. Analysts anticipate that MediWound will post -2.03 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Essex Investment Management Co. LLC lifted its holdings in shares of MediWound by 241.6% during the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock valued at $1,888,000 after buying an additional 93,705 shares during the last quarter. Janney Montgomery Scott LLC acquired a new stake in MediWound in the first quarter valued at approximately $427,000. Rosalind Advisors Inc. grew its position in MediWound by 5.7% in the second quarter. Rosalind Advisors Inc. now owns 513,490 shares of the biopharmaceutical company’s stock worth $7,969,000 after acquiring an additional 27,500 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of MediWound during the 2nd quarter worth $342,000. Finally, Rhumbline Advisers bought a new position in shares of MediWound during the 2nd quarter valued at $131,000. 46.83% of the stock is owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.